Dmitri Simberg
Impact in
- Biomaterials top 0.2%
- Nanoparticle-Based Drug Delivery
- Immunology top 2%
- Immunotherapy and Immune Responses
- Complement system in diseases
Papers in
- Biomaterials 42
- Nanoparticle-Based Drug Delivery 42
- Immunology 39
- Complement system in diseases 30
- Co-authors
- S. Moein Moghimi (37 shared papers)Priya Karmali (6 shared papers)Yechezkel Barenholz (13 shared papers)Guankui Wang (32 shared papers)Erkki Ruoslahti (8 shared papers)Nirmal K. Banda (20 shared papers)Yeshayahu Talmon (4 shared papers)Michael J. Sailor (5 shared papers)
- Journals
- ACS Nano (13 papers)Journal of Controlled Release (11 papers)Nature Nanotechnology (4 papers)Bioconjugate Chemistry (4 papers)Molecular Pharmaceutics (4 papers)
- Partner nations
- United StatesUnited KingdomIsrael
In The Last Decade
Dmitri Simberg
100 papers receiving 4.9k citations
Dmitri Simberg's Hit Papers
Peers
Comparison fields: 5 of 132
- Biomaterials 2.2k
- Immunology 924
- Pharmaceutical Science 244
- Surfaces, Coatings and Films 269
- Biomedical Engineering 1.6k
Countries citing papers authored by Dmitri Simberg
This map shows the geographic impact of Dmitri Simberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dmitri Simberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dmitri Simberg more than expected).
Fields of papers citing papers by Dmitri Simberg
This network shows the impact of papers produced by Dmitri Simberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dmitri Simberg. The network helps show where Dmitri Simberg may publish in the future.
Co-authors
The 25 scholars most cited alongside Dmitri Simberg, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 107 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo Hit paper breakdown → | 2016 | 498 |
| 2 | 2007 | 399 | |
| 3 | 2011 | 317 | |
| 4 | 2017 | 280 | |
| 5 | 2009 | 268 | |
| 6 | 2018 | 262 | |
| 7 | 2004 | 217 | |
| 8 | 2001 | 176 | |
| 9 | 2018 | 164 | |
| 10 | 2009 | 148 | |
| 11 | 2018 | 113 | |
| 12 | 2003 | 105 | |
| 13 | 2005 | 93 | |
| 14 | 2014 | 85 | |
| 15 | 2015 | 85 | |
| 16 | 2011 | 81 | |
| 17 | 2017 | 81 | |
| 18 | 2014 | 69 | |
| 19 | 2013 | 62 | |
| 20 | 2014 | 62 |
About Dmitri Simberg
Dmitri Simberg is a scholar working on Biomaterials, Immunology, Molecular Biology, Biomedical Engineering and Hematology, having authored 107 papers that have together received 5.0k indexed citations. Recurring topics across this work include Nanoparticle-Based Drug Delivery (42 papers), Complement system in diseases (30 papers), RNA Interference and Gene Delivery (22 papers), Nanoplatforms for cancer theranostics (12 papers), Monoclonal and Polyclonal Antibodies Research (9 papers), Blood groups and transfusion (9 papers), SARS-CoV-2 and COVID-19 Research (7 papers) and COVID-19 Impact on Reproduction (6 papers). The work is most often cited by research in Biomaterials (2.2k citations), Immunology (924 citations), Pharmaceutical Science (244 citations), Surfaces, Coatings and Films (269 citations) and Biomedical Engineering (1.6k citations). Dmitri Simberg has collaborated with scholars based in United States, United Kingdom and Israel. Frequent co-authors include S. Moein Moghimi, Priya Karmali, Yechezkel Barenholz, Guankui Wang, Erkki Ruoslahti, Nirmal K. Banda, Yeshayahu Talmon, Michael J. Sailor, Linping Wu and V. Michael Holers. Their work appears in journals such as ACS Nano, Journal of Controlled Release, Nature Nanotechnology, Bioconjugate Chemistry and Molecular Pharmaceutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.